Hudson Bay Capital Management LP Argenx Se Transaction History

Hudson Bay Capital Management LP

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $292,996 - $371,625	823 Added 5.81%	15,000 $6.45 Million
Q1 2024 May 15, 2024	SELL	$356.95 - $413.29 $30.3 Million - $35.1 Million	-84,826 Reduced 85.68%	14,177 $5.58 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $10.5 Million - $15.7 Million	31,000 Added 45.59%	99,003 $37.7 Million
Q3 2023 Nov 14, 2023	BUY	$369.35 - $548.43 $11.5 Million - $17 Million	31,067 Added 84.11%	68,003 $33.4 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $1.56 Million - $1.83 Million	-4,335 Reduced 10.5%	36,936 $14.4 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $13.8 Million - $16.7 Million	41,271 New	41,271 $15.4 Million

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $34.8B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Hudson Bay Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Hudson Bay Capital Management LP with notifications on news.